Schmerzmedikamente bei Nierenpatienten

Für die Schmerztherapie bei Nierenkranken und Dialysepatienten sind besondere Kenntnisse nötig. Denn zunächst einmal können bestimmte Analgetika die Nieren schädigen. Hinzu kommt, dass die Dosierung von Koanalgetika wie Antikonvulsiva, Antidepressiva und Antipsychotika i. d. R. an die Nierenfunktion angepasst werden muss. Außerdem besteht bei einer Morphintherapie durch die Kumulationskinetik ein erhöhtes Risiko für eine Atemdepression.

Abstract

Analgesic drug therapy in kidney patients needs special expertise. Patients with kidney disease frequently have pain and they have chronic pain more than others. Some analgesic drugs have a nephrotoxic potential and co-analgesics such as anticonvulsive, antidepressive and antipsychotic drugs need a dose adjustment to kindey function. When treating kidney patients with morphine, the accumulation kinetics of the M6 glucuronide must be observed. Otherwise, the risk increases for respiratory depression.

Schlüsselwörter

Schmerztherapie - Nierenerkrankung - Dosisanpassung - Morphin - Dialyse

Key words

analgesic drugs - kidney disease - dose adjustment - morphine - dialysis

Publikationsverlauf

Artikel online veröffentlicht:
03. August 2021

• Literatur

• 1 James G, Nyman E, Fitz-Randolph M. et al. Characteristics, Symptom Severity, and Experiences of Patients Reporting Chronic Kidney Disease in the PatientsLikeMe Online Health Community: Retrospective and Qualitative Study. J Med Internet Res 2020; 22: e18548
• 2 Kotsis FK, Secula P, Schultheiss UT. et al Berichtete Einnahme von Medikamenten und Level von Medikamenten-Metaboliten im Urin in der German Chronic Kidney Disease (GCKD) Studie. Berlin: Deutsche Gesellschaft für Nephrologie DGfN Kongress; 2020 FV20
• 3 Grekhov RA, Suleimanova GP, Trofimenko AS. et al. Psychosomatic Features, Compliance, and Complementary Therapies in Rheumatoid Arthritis. Curr Rheumatol Rev 2020; 16: 215-223
• 4 Edwards RR, Dworkin RH, Sullivan MD. et al. The Role of Psychosocial Processes in the Development and Maintenance of Chronic Pain. J Pain 2016; 17 (Suppl. 09) T70-T92
• 5 Thorell K, Midlöv P, Fastbom J. et al. Importance of potentially inappropriate medications, number of chronic conditions and medications for the risk of hospitalisation in elderly in Sweden: a case-control study. BMJ Open 2019; 9: e02947
• 6 Raouf M, Bettinger J, Wegrzyn EW. et al. Pharmacotherapeutic Management of Neuropathic Pain in End-Stage Renal Disease. Kidney Dis (Basel) 2020; 6: 157-167
• 7 Bausewein C, Simon ST, Pralong A. et al. Palliative Care of Adult Patients With Cancer. Dtsch Arztebl Int 2015; 112: 863-870
• 8 Lötsch J, Dudziak R, Freynhagen R. et al. Fatal respiratory depression after multiple intravenous morphine injections. Clin Pharmacokinet 2006; 45: 1051-1060
• 9 Moist L. Pain management in a patient with kidney failure. Clin J Am Soc Nephrol 2020; 15: 1657-1659
• 10 Angst MS, Bührer M, Lötsch J. Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. Anesthesiology 2000; 92: 1473-1476
• 11 Ishida JH, McCulloch CE, Steinman MA. et al. Opioid Analgesics and Adverse Outcomes among Hemodialysis Patients. Clin J Am Soc Nephrol 2018; 13: 746-753
• 12 Thomas C. A Patient's Perspective on Benzodiazepines, Co-Dispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis. Clin J Am Soc Nephrol 2020; 15: 743-744
• 13 Oluyase AO, Raistrick D, Hughes E. et al. The appropriateness of psychotropic medicines: an interview study of service users attending a substance misuse service in England. Int J Clin Pharm 2019; 41: 972-980
• 14 Han Y, Balkrishnan R, Hirth RA. et al. Assessment of Prescription Analgesic Use in Older Adults With and Without Chronic Kidney Disease and Outcomes. JAMA Netw Open 2020; 3: e2016839
• 15 Zaporowska-Stachowiak I, Szymański K, Oduah MT. et al. Midazolam: Safety of use in palliative care: A systematic critical review. Biomed Pharmacother 2019; 114: 108838
• 16 Di Forti M, Quattrone D, Freeman TP. et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 2019; 6: 427-436
• 17 Fisher E, Eccleston C, Degenhardt L. et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a protocol for an overview of systematic reviews and a systematic review of randomised controlled trials. Pain Rep 2019; 4: e741
• 18 Likar R, Köstenberger M, Nahler G. Cannabidiol in cancer treatment. Schmerz 2020; 34: 117-122
• 19 Cheung KWA, Chan PC, Lo SH. The use of ketamine in the management of refractory cancer pain in a palliative care unit. Ann Palliat Med 2020; 9: 4478-4489
• 20 Wheeler KE, Grilli R, Centofanti JE. et al. Adjuvant Analgesic Use in the Critically Ill: A Systematic Review and Meta-Analysis. Crit Care Explor 2020; 2: e0157